Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma

BMC Medical Research Methodology

Annibale Biggeri¹  Oriana Nanni²  Annalisa Pezzi³  Elena Zamagni³  Michele Cavo³ 

[1] Dipartimento di Statistica, Informatica, Applicazioni “Giuseppe Parenti” (DiSIA), Università di Firenze;Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS;Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico Sant’Orsola-Malpighi;

关键词: Selection bias;    Weighting sample;    Propensity score;    Causal effect;    RCT;    Compliance;   

DOI  :  10.1186/s12874-016-0253-9

来源: DOAJ

【 摘 要 】

Abstract Background Randomization procedure in randomized controlled trials (RCTs) permits an unbiased estimation of causal effects. However, in clinical practice, differential compliance between arms may cause a strong violation of randomization balance and biased treatment effect among those who comply. We evaluated the effect of the consolidation phase on disease-free survival of patients with multiple myeloma in an RCT designed for another purpose, adjusting for potential selection bias due to different compliance to previous treatment phases. Methods We computed two propensity scores (PS) to model two different selection processes: the first to undergo autologous stem cell transplantation, the second to begin consolidation therapy. Combined stabilized inverse probability treatment weights were then introduced in the Cox model to estimate the causal effect of consolidation therapy miming an ad hoc RCT protocol. Results We found that the effect of consolidation therapy was restricted to the first 18 months of the phase (HR: 0.40, robust 95 % CI: 0.17-0.96), after which it disappeared. Conclusions PS-based methods could be a complementary approach within an RCT context to evaluate the effect of the last phase of a complex therapeutic strategy, adjusting for potential selection bias caused by different compliance to the previous phases of the therapeutic scheme, in order to simulate an ad hoc randomization procedure. Trial registration ClinicalTrials.gov: NCT01134484 May 28, 2010 (retrospectively registered) EudraCT: 2005-003723-39 December 17, 2008 (retrospectively registered)

【 授权许可】

Unknown